Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, ...

Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

Biogen (NASDAQ:BIIB – Free Report) had its price objective decreased by Mizuho from $251.00 to $207.00 in a research note published on Thursday,Benzinga reports. Mizuho currently has an outperform ...

The volume of shares traded was 1.70 million exceeding the average volume of 1.31 million. In recent trading, Biogen Inc (BIIB) stock price has shown some volatility, fluctuating -1.31% over the last ...

The volume of shares traded was 1.62 million exceeding the average volume of 1.27 million. In recent trading, Biogen Inc (BIIB) stock price has shown some volatility, fluctuating -5.91% over the last ...

Samsung Biologics has announced another significant manufacturing agreement, securing a $668m contract with a Europe-based ...

Mizuho lowered the firm’s price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated ...

Today, Benzinga 's options scanner spotted 9 uncommon options trades for Biogen. This isn't normal. The overall sentiment of ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

The best of the companies that don't pay dividends are fast-growing businesses that invest all of their profits in new growth ...

Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...

Fintel reports that on November 18, 2024, Needham downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.